The global protein design and engineering market is forecast to expand from $7.62 billion in 2025 to $15.71 billion by 2030, driven by advances in AI, synthetic biology, and demand for precision therapeutics.
Growth is underpinned by rapid development of AI-powered drug discovery platforms, rising investment in personalized medicine, and wider adoption of synthetic biology across the life sciences sector.
What happened
The global protein design and engineering market is projected to grow from $7.62 billion in 2025 to $8.79 billion in 2026, a compound annual growth rate of 15.4%, and reach $15.71 billion by 2030 at a CAGR of 15.6% between 2026 and 2030.
Why it matters
AI-powered drug discovery, synthetic biology adoption, and rising investment in precision medicine are reshaping how pharmaceutical companies develop biologics and vaccines. Protein engineering improves the stability, efficacy, manufacturability and target specificity of therapeutic proteins, making it central to the next wave of drug development.
What to watch
Key growth drivers include AI-driven protein structure prediction, computational modeling for novel enzyme design, de novo protein engineering for therapeutics, and integration of high-throughput screening into protein optimization workflows. Asia-Pacific is flagged as offering expansion potential.
Ask the AI about this article →
The protein design and engineering market is at an inflection point driven by convergence of AI advances and therapeutic demand. The market's projected growth from $7.62 billion in 2025 to $15.71 billion by 2030—a sustained CAGR of roughly 15.5%—reflects a sector-wide shift toward computational and AI-enabled drug discovery. This acceleration is not solely a result of new technology; it reflects maturation of supporting disciplines: recombinant DNA technologies, structural biology research tools, and molecular biology methodologies have created the infrastructure upon which AI-driven protein design platforms now operate.
The market's expansion is anchored in three interconnected trends. First, AI-powered drug discovery platforms are reducing cycle time and cost in protein optimization. Second, pharmaceutical companies are investing heavily in precision therapeutics and personalized medicine, both of which depend on tailored protein engineering. Third, synthetic biology adoption across the life sciences enables broader access to engineered biologics and custom biomaterials. These factors reinforce each other: better computational tools attract more R&D investment; more investment accelerates tool adoption; broader adoption drives down costs and lowers barriers to entry for smaller organizations.
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytime
Ask AI anything about this article. Q&As are published on this page for other readers too.
Apple is laying off staff in its Vision team as part of a strategic shift away from VR headsets toward AI-driv…
HP Korea has formed a partnership with Upstage, a large language model (LLM) startup, to advance its localized…
DIGITIMES analyst Joyce Chen stated on August 20 at a semiconductor industry forum in Taipei that optical comm…
At the "AI on Chips: Semiconductor Industry Trends Forum" hosted by DIGITIMES, industry experts highlighted th…
JCET Group posted record first-half 2026 revenue, driven by demand from artificial intelligence infrastructure…
Scott Ortkiese, CEO of Faulkner Capital Holdings, argues that AI infrastructure risk has been routed away from…
